INSERM U851 et UMS3444/US8, Université de Lyon, 21 Avenue Tony Garnier, Lyon, France.
Int Arch Allergy Immunol. 2011;156(4):387-96. doi: 10.1159/000323940. Epub 2011 Aug 9.
Regulatory T cells contribute to peripheral immune tolerance, yet their ability to control immediate-type hypersensitivity (ITH) reactions involved in IgE-mediated food allergy is still poorly documented.
We investigated in mice whether CD4+CD25+ regulatory T cells could control ITH to β-lactoglobulin (BLG), a major allergen in cow's milk.
C3H/HeOuJ mice were sensitized by repeated oral gavage with BLG plus cholera toxin as adjuvant and orally challenged with BLG alone to elicit allergic symptoms. Mice were treated with the anti-CD25 mAb (PC61) before sensitization. Oral sensitization (afferent phase of ITH) was assessed by production of BLG-specific serum antibodies and Th1/Th2-type cytokines by specific CD4+ T cells in mesenteric lymph nodes. ITH was elicited by oral BLG challenge (efferent phase of ITH) and we monitored symptom scores, numbers and function of intestinal mast cells and serum level of the mucosal mast cell protease mMCP-1.
Upon oral BLG challenge, orally sensitized mice developed only mild clinical signs. Anti-CD25 mAb-treated mice exhibited enhancement of both BLG-specific CD4+ T cell priming with IL-4, IL-5, IL-13 and IFN-γ production and total IgE, and BLG-specific IgE, IgG1 and IgG2a in serum. Anti-CD25 mAb treatment caused more severe symptoms upon BLG challenge, which correlated with enhanced serum levels of the mucosal mast cell protease mMCP-1.
These data document that constitutive CD4+CD25+ regulatory T cells alleviate clinical signs of ITH to dietary BLG by modulating the priming of BLG-specific T and B cell responses during oral sensitization and enhancing mast cell degranulation.
调节性 T 细胞有助于外周免疫耐受,但它们控制 IgE 介导的食物过敏中涉及的即刻型过敏反应(ITH)的能力仍记录甚少。
我们在小鼠中研究了 CD4+CD25+调节性 T 细胞是否可以控制β-乳球蛋白(BLG)的 ITH,BLG 是牛奶中的主要过敏原。
C3H/HeOuJ 小鼠通过反复口服 BLG 加霍乱毒素作为佐剂进行致敏,并单独口服 BLG 进行过敏症状激发。在致敏前用抗 CD25 mAb(PC61)处理小鼠。通过肠系膜淋巴结中 BLG 特异性血清抗体和 Th1/Th2 型细胞因子的产生来评估口服致敏(ITH 的传入相)。通过口服 BLG 挑战(ITH 的传出相)引发 ITH,并监测症状评分、肠道肥大细胞的数量和功能以及粘膜肥大细胞蛋白酶 mMCP-1 的血清水平。
在口服 BLG 挑战后,口服致敏的小鼠仅表现出轻微的临床症状。抗 CD25 mAb 处理的小鼠表现出 BLG 特异性 CD4+T 细胞的初始增强,伴有 IL-4、IL-5、IL-13 和 IFN-γ 的产生以及总 IgE 和血清中 BLG 特异性 IgE、IgG1 和 IgG2a 的增加。抗 CD25 mAb 处理导致 BLG 挑战时更严重的症状,这与粘膜肥大细胞蛋白酶 mMCP-1 的血清水平升高相关。
这些数据表明,组成型 CD4+CD25+调节性 T 细胞通过调节口服致敏期间 BLG 特异性 T 和 B 细胞反应的初始以及增强肥大细胞脱颗粒作用,减轻对饮食 BLG 的 ITH 的临床症状。